Studying the Safety of Discontinuing DMTs in MS Older Adults

Host: Andrew Wilner, MD, FACP, FAAN Guest: John R. Corboy, MD Disease-modifying therapies (DMTs) reduce disease activity and slow the progression of disability in multiple sclerosis. But there were some challenges that came out of this recent study. To discuss the findings from this trial, Dr. Andrew Wilner is joined by Dr. John Corboy, Professor of Neurology and the Director of the Rocky Mountain MS Center at the University of Colorado.